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Abstract: Thiourea-based molecules cause pulmonary edema when administered to rats at relatively low
doses. However, rats survive normally lethal doses after prior exposure to a lower, nonlethal dose; this
phenomenon is known as tolerance. The present study investigated the morphological and functional
aspects of acute lung injury (ALI) induced by methylphenylthiourea (MPTU) in the Wistar rat and
the pulmonary response involved in prevention of the injury. We identified pulmonary endothelial cells
as the main target of acute MPTU injury; they exhibited ultrastructural alterations that can result in
increased vascular permeability. In tolerant rats, the lungs showed only transient endothelial changes,
at 24-hour post dosing, and mild type II pneumocyte hyperplasia on day 7 post dosing. They exhibited
glutathione levels similar to the controls and increased expression of flavin-containing monooxygenase 1
(FMO1), the enzyme responsible for bioactivation of small thioureas in the laboratory rat. Incubation of
rat pulmonary microsomal preparations with MPTU inhibited FMO activity, indicating that tolerance
is related to irreversible inhibition of FMOs. The rat model of thiourea-induced pulmonary toxicity and
tolerance represents an interesting approach to investigate certain aspects of the pathogenesis of ALI and
therapeutic approaches to lung diseases, such as acute respiratory distress syndrome.
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50 Abbreviations: ALI Acute lung injury, ANTU Alpha-naphthylthiourea, AQP-5 
51 Aquaporin 5,  ARDS acute respiratory distress syndrome,  CYP cytochome P450, 
52 FMO Flavin-containing monooxygenase, GSH Gluthatione, HE Hematoxylin and 
53 eosin, HD High dose of MPTU (5 mg/kg), LD Low dose of MPTU (0.5 mg/kg),MI 
54 Methimazole, MPTU Methylphenylthiourea, PCNA Proliferating cell nuclear antigen, 
55 PD Post dosing, S Substrate, SP-C Surfactant protein C, RT Reverse transcription, 
56 TEM Transmission electron microscopy, VO velocity
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59 Thiourea-based molecules cause pulmonary edema when administered to rats 
60 at relatively low doses. However, rats survive normally lethal doses after prior 
61 exposure to a lower, non-lethal dose; this phenomenon is known as tolerance. 
62 The present study investigated the morphological and functional aspects of 
63 acute lung injury (ALI) induced by methylphenylthiourea (MPTU) in the Wistar 
64 rat and the pulmonary response involved in prevention of the injury. We 
65 identified pulmonary endothelial cells as the main target of acute MPTU injury; 
66 they exhibited ultrastructural alterations that can result in increased vascular 
67 permeability. In tolerant rats the lungs showed only transient endothelial 
68 changes, at 24 hr post dosing, and mild type II pneumocyte hyperplasia on day 
69 7 post dosing. They exhibited glutathione levels similar to the controls and 
70 increased expression of flavin-containing monooxygenase 1 (FMO1), the 
71 enzyme responsible for bioactivation of small thioureas in the laboratory rat. 
72 Incubation of rat pulmonary microsomal preparations with MPTU inhibited 
73 FMO activity, indicating that tolerance is related to irreversible inhibition of 
74 FMOs. The rat model of thiourea-induced pulmonary toxicity and tolerance 
75 represents an interesting approach to investigate certain aspects of the 
76 pathogenesis of ALI and therapeutic approaches to lung diseases, such as 
77 acute respiratory distress syndrome.
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79 Acute single dose toxicity of thiourea in laboratory rodents and dogs is 
80 characterized by severe pulmonary edema.1 Lung toxicity requires metabolic 
81 activation of thiourea2, which is mainly carried out during phase I metabolism 
82 by the flavin containing monooxygenase enzymes (FMOs), of which thiourea 
83 is an excellent substrate.3 FMO oxygenation of lipophilic compounds 
84 containing heterophilic atoms produces more polar, readily excreted 
85 metabolites with reduced pharmacological and toxicological properties. 
86 However, FMO-mediated S-oxygenation of small chemical groups such as 
87 sulphides and disulphides, thioethers, thiols and thioureas represents an 
88 exception to this rule and produces a sulphoxide, often through an 
89 intermediate sulphenic acid.3 Sulphenic acids, which can be further oxidized 
90 to sulphinic and sulphonic acids, are extremely reactive electrophiles and are 
91 thought to react promptly with the parent drug or with nucleophiles such as 
92 glutathione (GSH) or other sulfhydryls to produce disulphides which disrupt the 
93 redox balance and induce oxidative stress, eventually resulting in irreversible 
94 modification of cellular proteins. 4,5 
95 The expression of the FMO genes varies considerably between different 
96 animal species6, despite the relatively low number of genes (five functional 
97 members, FMO1 to FMO5) and allelic variants of this protein family. In the wild 
98 rat lung, FMO1 and FMO2 seem to be the only FMO members expressed at 
99 significant levels.7 In laboratory rats, FMO2 is mutated, encodes a truncated, 
100 catalytically inactive protein and does not contribute to the bioactivation of 
101 thiourea.7
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102 Investigations into the toxic effects of thioureas were mainly conducted during 
103 the years surrounding World War II, when the risk of rat-borne epidemics was 
104 extraordinarily high; they led to the synthesis of alpha-naphthylthiourea 
105 (ANTU), an organosulphur compound containing the thiourea moiety and a 
106 naphthalene group.8 ANTU was shown to cause severe respiratory distress in 
107 rats, resulting from pulmonary edema and pleural effusion, and subsequently 
108 became popular as an experimental model of lung edema and acute 
109 respiratory distress syndrome (ARDS).9 ANTU proved to be an effective 
110 rodenticide but with major drawbacks10, one of which was that rats that had 
111 survived a sublethal dose of the rodenticide were able to withstand subsequent 
112 lethal doses.11 Several studies have attempted to explain the mechanism 
113 underlying tolerance to ANTU. 2, 12-13 Proliferation of epithelial cells in the lung 
114 was considered as a possible mechanism,12 based on the observation that 
115 administration of keratinocyte growth factor to rats attenuated the pulmonary 
116 edema induced by the rodenticide.14 However, the literature in this field has so 
117 far failed to illustrate in detail the pathological processes in the lung associated 
118 with tolerance and a definitive conclusion on the mechanism underlying the 
119 acquired tolerance to thiourea has not been drawn. Yet, the elucidation of the 
120 tolerance mechanism might bring new insights into potential therapeutic 
121 options for pulmonary conditions characterized by increased vascular 
122 permeability and oxidative stress, such as ARDS or adverse drug reactions 
123 (e.g. to bleomycin).15
124 The present study aimed to characterize the morphological changes and the 
125 mechanisms connected with the development of and adaptation to the acute 
126 pulmonary toxicity induced by a thiourea derivate (methylphenylthiourea, 
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127 henceforth named MPTU) in laboratory rats. Mechanistic knowledge in this 
128 field is particularly relevant since reactive oxygen scavengers, such as N-
129 acetyl-cysteine or dimethylthiourea, are used as therapeutic adjuncts to 
130 prevent oxidant-mediated damage to the lung; these scavengers have been 
131 extensively studied in animal models of ARDS,16 but their efficacy might vary 
132 based on the underlying pathogenesis. We hypothesized that the induction of 
133 tolerance after administration of a sublethal dose of MPTU could result from 
134 either increased clearance of edema fluid, increased levels of sulfhydryl-
135 reducing agents, and/or altered expression/function of FMOs in the rat lungs 
136 and tried to address each of these postulations (Fig.1). 
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137 Materials and Methods
138 Test article
139 All experiments were conducted using a small thiourea derivate (MPTU, a 
140 phenylthiourea with a methyl substitution in position 6), provided by BASF 
141 Professional & Speciality Solutions, BASF plc, United Kingdom. MPTU was 
142 formulated on the same day and administered by oral intubation to rats, whilst 
143 control rats received only the vehicle (polyethylene glycol 
144 200:triethanolamine).
145
146 Experimental animal work 
147 Male Wistar rats (6-7 weeks, 200-250 g) were obtained from Charles River 
148 Laboratories (Margate, UK). Upon arrival, all rats were maintained in 
149 environmentally controlled rooms with 12 hr dark-and-light cycles. They were 
150 caged in groups, with tap water and commercial rat food available ad libitum. 
151 All animal experiments were undertaken in accordance with criteria outlined in 
152 a license granted by the designated Scientific Procedures Establishment 
153 under the Animals (Scientific Procedures) Act 1986, which implements in the 
154 UK the EU Directive 86/609/EEC. The experimental protocols were approved 
155 by the University of Liverpool Animal Ethics Committee.
156 In order to identify the target organs and the toxicological changes induced by 
157 a lethal dose of MPTU, Wistar rats (n = 6) received po (gavage) 5 mg/kg of the 
158 test article, a dose that had been previously determined to exceed the LD50 in 
159 acute toxicity studies conducted at our facility (LD50 between 2 and 5 mg/kg; 
160 results not shown), and were euthanized at 6 hr post dosing (pd), after they 
161 had developed severe clinical signs. In a second pilot experiment, aimed to 
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162 study the development of tolerance, rats (n = 5) received a low oral dose 
163 (0.5 mg/kg) of MPTU, followed after 3 hr by a second, high dose (5 mg/kg). 
164 The tolerogenic dose was established based on a previously conducted 
165 experiment,12 which achieved tolerance to a lethal dose of ANTU after the 
166 administration of a 10× lower tolerogenic dose. Clinical signs and mortality 
167 were monitored during the following 7 days (d). Based on the results of this 
168 experiment, a 14 d tolerance study was designed, as illustrated in Figure 2. 
169 Briefly, this study included four dose groups that received po the vehicle, the 
170 high dose (HD, 5 mg/kg) of MPTU, the low dose (LD, 0.5 mg/kg) of MPTU or 
171 the LD and HD combined. In the LD and LD+HD groups, 3 hr, 6 hr, 24 hr, 7 d 
172 and/or 14 d euthanasia endpoints were selected; all groups were comprised 
173 of 3 rats. In an attempt to determine whether animals previously dosed with 
174 the LD of MPTU exhibited prolonged decreased susceptibility to a lethal dose 
175 of the compound, two cohorts of three rats that had previously been 
176 administered the LD or the LD+HD received a further dose of 5 mg/kg in the 
177 morning of day 14 post initial treatment. All rats in these two additional cohorts 
178 were euthanized 6 hr after the challenge.
179 In all studies, clinical signs were recorded at 0, 0.5, 1, 2, 4, 6 and/or 8 hr pd 
180 and then twice daily, until the end of the experiments. Any animal that exhibited 
181 clinical signs such as tachypnea and dyspnea was constantly monitored and 
182 was culled according to the standard operating procedures in force before 
183 experiencing severe pain, distress or death.
184
185 Post mortem examination
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186 Rats were euthanized with carbon dioxide, followed by exsanguination. A 
187 complete necropsy, including a thorough external and internal gross post 
188 mortem examination was performed on each rat. Any fluid that was present in 
189 the thoracic cavity was aspirated with a syringe, quantified and cytological 
190 specimens prepared, stained with May Grunwald Giemsa, and examined with 
191 a light microscope. A comprehensive histological examination including all 
192 organs and tissues was carried out in the first acute toxicity study (full 
193 pathological screening), whilst the histological analysis in all further 
194 experiments was limited to selected organs (brain, heart, lungs, liver, kidneys, 
195 thymus and spleen). The lungs were removed and, after ligation of the right 
196 hilus, fixed through gentle intratracheal instillation of 2 mL 4% buffered 
197 paraformaldehyde (pH 7.4). In the acute toxicity study, the lungs were not 
198 instilled with the fixative to allow assessment and quantification of intraalveolar 
199 fluid and cells. Light and transmission electron microscopy were performed on 
200 the left lobes and the right cranial lobes, respectively. The remaining right 
201 lobes (median, caudal and accessory lobes) were snap frozen in liquid 
202 nitrogen, stored at -80°C and used for the determination of GSH levels and for 
203 RT-qPCR. After 48 hr fixation, the left lobe was trimmed, processed and 
204 routinely paraffin wax embedded for histological examination. Serial sections 
205 (3-5 µm thick) were prepared and stained with hematoxylin and eosin (HE) and 
206 subjected to immunohistological staining. Microscopic findings in the HE-
207 stained slides were classified with standard pathological nomenclature and 
208 severities of findings were graded on a scale of 1 to 5 as minimal (1), mild (2), 
209 moderate (3), marked (4), or severe (5). Grades of severity for microscopic 
Page 12 of 53
For Review Purposes Only - Do Not Cite www.toxpath.org






























































210 findings were subjective; minimal was the least extent discernible and severe 
211 was the greatest extent possible.17
212 Immunohistology was employed for the characterization of the cells populating 
213 the alveolar unit and to determine the presence of apoptotic and proliferating 
214 cells in the alveoli, detecting the following antigens: aquaporin 5 (AQP-5; type 
215 I pneumocytes), surfactant protein C (SP-C, type II pneumocytes), lysozyme 
216 (alveolar macrophages and type II pneumocytes)18, von Willebrand factor 
217 (endothelial cells), cleaved caspase 3 (apoptotic cells) and proliferating cell 
218 nuclear antigen (PCNA, proliferating cells). See supplementary material at 
219 http://tpx.sagepub.com/supplemental for details regarding the 
220 immunohistological protocols and specifics of the antibodies used in this study.
221 SP-C- and lysozyme-expressing cells were counted using ten 400 × 
222 magnification (i.e. high power) fields, avoiding areas at the periphery of the 
223 section or regions containing large bronchial and vascular structures. All 
224 positive and negative cells were counted in each field, and immunostained 
225 cells were quantified as a percentage of the total cells. For the quantification 
226 of PCNA-positive proliferating cells in the lung of rats from the tolerance study, 
227 twenty random fields were evaluated at the 400 × magnification and the 
228 proliferative index was expressed as the average number of PCNA-positive 
229 cells/field. Occasional positive cells other than alveolar lining cells, such as 
230 bronchial or bronchiolar epithelial cells, endothelial cells in arteries and veins 
231 as well as leukocytes were not included in the counts.
232 Transmission electron microscopy (TEM) was conducted on the lungs of 
233 selected animals (one rat/group, tolerance study). For this purpose, 
234 approximately 1 mm3 samples of lung tissue from the cranial right lobe of all 
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235 animals were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, 
236 pH 7.4, for 24 hr and subsequently routinely embedded in epoxy resin. Semi-
237 thin sections were prepared and stained with toluidine blue. From the semi-
238 thin sections of one rat/group, areas of interest were chosen and ultrathin 
239 sections (60 nm) prepared, stained with Reynold’s lead citrate and examined 
240 with a transmission electron microscope (Philips EM208S, Cambridge, UK).
241
242 Determination of pulmonary glutathione (GSH) levels 
243 Total (oxidized and reduced) GSH amounts in the lungs were determined as 
244 described previously19 from all rats in the tolerance study and normalized to 
245 the amount of proteins measured using the Lowry assay.20 Briefly, 
246 approximately 200 mg of lung tissue (right middle and caudal lobes) was 
247 homogenized in 200 µL 6.5% (w/v) 5 sulfosalicylic acid and 800 µL GSH stock 
248 buffer (143 mM NaH2PO4  and 6.3 mM EDTA in distilled water, pH 7.4), using 
249 a manual glass homogenizer. The homogenates were incubated on ice for 10 
250 min and then pelleted through centrifugation at 20,000 g for 5 min. The 
251 supernatant was collected and 1 mL of 1 M NaOH was added to each protein 
252 pellet and incubated at 60°C for 1 hr. The supernatant was used for the GSH 
253 assay which represented modified, previously published methods.21,22  For the 
254 assay, 20 µL of supernatant diluted 1:10 and 1:20 or GSH standards (0-80 
255 nM/mL) were added in duplicate to a 96-well microplate, followed by the 
256 addition of 20 µL GSH stock buffer to neutralize the pH. 200 µL of daily assay 
257 reagent (1 mM 5-5'-dithiobis[2-nitrobenzoic acid], 0.34 mM NADPH in GSH 
258 stock buffer) was added to each well. This was followed by an exact 5 min 
259 incubation at room temperature. The enzymatic reaction described above was 
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260 initiated by the addition of 50 µL GSH reductase (6.96 U/mL in GSH stock 
261 buffer, Sigma, Poole, UK). GSH formation was followed at 412 nm for 2.5 min 
262 in a MRX microplate reader (Dynotech Laboratories, Billinghurst, UK). All 
263 reagents were covered in aluminum foil to protect them from light.
264
265 RT-qPCR for FMO1 and FMO2 mRNA quantification
266 Reverse transcription (RT) was performed in all animals from the tolerance 
267 study on purified RNA extracted from lung tissue using TRIzol LS RNA reagent 
268 (Thermo Fisher Scientific, Paisley, UK), employing a TaqMan RNA reverse 
269 transcription kit (Thermo Fisher Scientific). Quantitative (q)PCR experiments 
270 were carried out following MIQE guidelines23 and using an Opticon Monitor 2 
271 real time PCR machine (MJ research, Biorad, Watford, UK). SYBR Green I-
272 based Master Mix (SYBRGreen JumpStart Taq ReadyMix, Sigma) and pre-
273 developed upstream and downstream primers specific to the FMO1 and FMO2 
274 genes were used according to the manufacturer’s protocol to quantitate the 
275 expression of genes in treated rats relative to the control animals. No-RT and 
276 no-template negative controls were included in each run. Results were 
277 evaluated using the Opticon Monitor software v.3.1.32 (MJ Research, Biorad) 
278 and normalized against the reference genes. See supplementary material at 
279 http://tpx.sagepub.com/supplemental for details on target (FMO1 and FMO2) 
280 and reference (glyceraldehyde 3-phosphate dehydrogenase; GAPDH) genes, 
281 primer sequences and detailed PCR protocols.
282
283 Enzyme assays
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284 FMO activity was estimated in rat lung microsomes, prepared from untreated 
285 rats as previously described,24,25 using the methimazole (MI) assay.26  Enzyme 
286 kinetics were determined using nine scalar concentrations (ranging from 5 µM 
287 to 1 mM) of the substrate and were calculated by plotting the reaction velocity 
288 (V0) as a function of the ratio between V0 and the substrate (S) concentration 
289 (Eadie–Hofstee diagram). The data sets were analyzed by GraphPad Prism 
290 version 6.00 for Windows (GraphPad Software, La Jolla, California, USA; 
291 www.graphpad.com, demo version) with a non-linear regression method that 
292 fits the Michaelis-Menten equation. The experiments were conducted in 
293 triplicate. Once the kinetic parameters were determined, FMO activity against 
294 MI over time (7 min) was measured, selecting a single substrate concentration 
295 (500 mM). The experiment was conducted in triplicate, at three different days. 
296 Negative controls, omitting the microsomal protein or MI, or composed 
297 exclusively of buffer, were included in each run. Enzyme inhibition was 
298 investigated, repeating the same experiment with the addition of the test 
299 article, MPTU (500 µM, resulting in a final concentration of approximately 75 
300 µg).
301 Note on data analysis. A statistical analysis was not performed because of 
302 the small number of animals in each treatment group. Due to the low sample 
303 size, there was not enough data that could be summarized using summary 
304 statistics. Instead, univariate scatterplots were employed to present the results 
305 and compare magnitude of values.
306 Statistical analysis 
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307 Statistical analysis was conducted on cell counts for SP-C-, lysozyme- and 
308 PCNA-expressing cells, pulmonary GSH levels and relative pulmonary FMO1 
309 and FMO2 mRNA levels, using the GraphPad Prism 8 software. Statistical 
310 analysis was performed by using the Kruskal Wallis non-parametric one-way 
311 ANOVA followed by Dunn´s multiple comparison test. All results were 
312 expressed as median ± standard deviation. Statistical significance was set at 
313 p < 0.05.
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315 Morphological features of acute pulmonary toxicity induced by MPTU
316 We carried out a single dose acute toxicity study in which rats received po a 
317 dose (5 mg/kg) of MPTU known to be lethal based on the results of a pilot 
318 acute toxicity study. Most animals were not eating or drinking from 3 hr pd 
319 onwards, and all rats were electively euthanized starting at 6 hr pd, after they 
320 had developed progressively severe clinical signs suggestive of impaired 
321 general health and respiratory distress, such as tachypnea, dyspnea, hunched 
322 posture and decreased motor activity. At necropsy, all treated rats exhibited 
323 pleural effusion (hydrothorax) with 3 to 6 ml of clear, transparent fluid in the 
324 thoracic cavity (Figure 3) the cytological examination of which showed low 
325 cellularity, with occasional individualized non-reactive mesothelial cells within 
326 a moderately proteinaceous background, indicating the fluid was a transudate.
327 The main histological changes were found in the lungs of the treated animals 
328 (Figure 4) and consisted of severe multifocal alveolar edema, characterized by 
329 the presence of a moderate to high amount of eosinophilic, homogenous or 
330 faintly granular material in the alveolar lumen (Figure 4B). Similar 
331 proteinaceous material was observed in the interstitium surrounding bronchi 
332 and blood vessels (interstitial edema; Figure 4D). A mild small increase in the 
333 number of alveolar macrophages (lysozyme-positive and SP-C-negative) was 
334 observed within the alveolar lumen. The alveolar architecture appeared 
335 otherwise unaltered, with a continuous lining by AQP-5-positive type I 
336 pneumocytes and von Willebrand factor-positive endothelial cells (data not 
337 shown). However, several treated rats exhibited scattered apoptotic alveolar 
338 lining cells, confirmed by their expression of cleaved caspase 3 (Figure 4F). 
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339 The ultrastructural examination (Figure 5) identified these apoptotic cells as 
340 endothelial cells. In the lungs of the rat euthanized at 6 hr pd, the general 
341 ultrastructural architecture of the alveolar unit was preserved. However, 
342 subendothelial blebs were detected within the alveolar capillaries (Figure 5B), 
343 these resulted from the separation of the endothelial cell from the underlying 
344 basal lamina and ranged from 100 nm to 1 μm in diameter. The blebs usually 
345 contained material with an electron density similar to that found in the capillary 
346 lumen, it was therefore interpreted as plasma. In addition, the endothelial lining 
347 appeared multifocally discontinuous (Figure 5C), as indicated by an irregular 
348 endothelial cell surface and occasional gap formation adjacent to intercellular 
349 junctions. In proximity to the gaps within or between endothelial cells, the 
350 alveolar lumen contained proteinaceous material with an electron density 
351 similar to that of plasma (alveolar edema; Figure 5D). Endothelial cells often 
352 appeared swollen and showed rarefaction or swelling of organelles and 
353 caveolae. Rarely, they also exhibited signs of irreversible injury, i.e. apoptosis 
354 (nuclear condensation and fragmentation; see also above, Figure 5C).
355
356 Morphological features of the pulmonary adaptive response induced by 
357 MPTU
358 The administration of non-lethal doses of the thiourea-based rodenticide 
359 ANTU to rats results in the development of tolerance to normally lethal doses.12   
360 In order to investigate whether this was also the case for MPTU, a pilot study 
361 was undertaken in which rats received a low dose (0.5 mg/kg) of MPTU, 
362 followed only 3 hr later by the normally lethal dose. Rats did not succumb to 
363 the high dose and only showed piloerection and mild tachypnea that both 
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364 resolved within less than 48 hr, suggesting they had developed the expected 
365 tolerance. In the 14 d tolerance study, which comprised rats that received the 
366 low dose alone (0.5 mg/kg; LD) and rats administered the low dose, followed 
367 3 hr later by the high dose (5 mg/kg; LD+HD), no relevant clinical signs or 
368 gross findings were observed in any animal. Histological changes in the lungs 
369 were similar in the two groups, as summarized in Table 1. While there was no 
370 evidence of alveolar and interstitial edema in LD rats euthanized at early time 
371 points (3, 6 and 24 hr), this was observed with mild severity in one LD+HD 
372 animal euthanized at 24 hr pd (3 and 6 hr time points were not included in the 
373 study design for LD+HD animals).Most rats in both groups exhibited minimal 
374 to mild type II pneumocyte (SP-C-positive) hyperplasia, which was observed 
375 at 24 hr pd, was most obvious at day 7 pd and was no longer present on day 
376 14 (Figures 6 and 7). PCNA immunohistology indicated an increase in 
377 proliferating alveolar lining epithelial cells consistent with type II pneumocytes 
378 at day 7. For comparison, only rare or no PCNA-positive alveolar cells were 
379 seen in control animals and in treated rats euthanized at early time points (LD 
380 rats: 3, 6 and 24 hr; LD+HD rats: 24 hr ) and at 14 d (Figure 6 and 7). In 
381 addition, an increase in alveolar macrophages was observed in LD animals at 
382 the 6 and 24 hr time points and LD+HD rats at 24 hr, similar in its extent to the 
383 increase seen in the high dose rats euthanized at 6 hr; a less pronounced 
384 increase, was observed at 7 and 14 d pd (Figure 7). 
385 Ultrastructural evaluation of the lungs at early time points (3, 6 and 24 hr pd) 
386 after the administration of tolerogenic doses of MPTU revealed endothelial 
387 blebs identical to those described in rats that had received the high dose 
388 (Figure 8A), however, these were far less frequently encountered and were 
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389 not detected at later time points (7 and 14 d pd). Other ultrastructural changes 
390 observed after administration of the high dose alone, such as gap formation 
391 and apoptosis of capillary endothelial cells, were not detected in the tolerant 
392 rats. Instead, undifferentiated pneumocytes (so called “intermediate” cells)27 
393 were found with increased frequency in rats euthanized at 24 hr and 7 d pd 
394 (Figure 8B, C). These cells exhibited large, oval to elongated, sometimes 
395 slightly indented, electron lucent nuclei with finely stippled chromatin and small 
396 amounts of cytoplasm devoid of lamellar bodies or other organelles, except for 
397 the endoplasmic reticulum.28,29  Such undifferentiated pneumocytes were very 
398 rare in the control animals, in tolerant rats at earlier time points, or in rats that 
399 had received the high dose only, where up to 3 cells/ultrathin section 
400 (approximately 200 mm2) were found. In the tolerant rats they were detected 
401 in almost every alveolar unit at the 24 hr and 7 d time points. 
402  All rats from the two additional cohorts that were euthanized 6 hr after 
403 challenge on day 14 with the high dose showed moderate dyspnea for up to 2 
404 hr; this correlated with a moderate to severe hydrothorax (3-5 mL). 
405 Histologically, pulmonary alveolar and interstitial edema was seen in all rats 
406 (data not shown), with similar incidence and severity as in rats receiving the 
407 high dose alone. These data suggest that tolerance was considerably 
408 attenuated 2 weeks after initial administration of a tolerogenic dose.
409
410 Effects of methylphenylthiourea on pulmonary GSH content and FMO 
411 expression
412 GSH levels in rats that had received the high dose, including those that were 
413 challenged on day 14 after initial tolerance induction, were reduced to 
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414 approximately 10% of those measured in the controls (Figure 9A). In rats 
415 administered MPTU at tolerogenic doses they were comparable or only 
416 moderately lower than in controls, suggesting that pulmonary antioxidant 
417 defenses are not increased in the tolerant lungs.
418 We explored the potential role of FMO1 in the development of thiourea-related 
419 toxicity and tolerance using RT-qPCR and also measured the FMO2 
420 transcripts, since although the enzyme is inactive and not present in the lungs 
421 of laboratory rats, its mRNA levels are not influenced by the FMO2 genotype 
422 and the absence of protein in the tissue is due to altered translation or protein 
423 instability rather than transcription impairment.7 In tolerant rats euthanized at 
424 24 h pd and later, regardless of the dose administered, FMO1 mRNA levels 
425 were significantly (p < 0.05) increased (Figure 9B), showing a 3-fold elevation 
426 at day 7 pd. Similarly, FMO2 mRNA levels were significantly (p < 0.01) higher 
427 in all treated animals than in controls, including those euthanized at the earliest 
428 time points (3 and 6 hr pd, Figure 9CB).
429
430 Analysis of enzyme inhibition
431 The Eadie-Hofstee graphical representation of methimazole (MI) S-oxidase 
432 activity catalyzed by FMOs in rat lung microsomal pools (Figure 10A) consisted 
433 of a straight line, suggesting that oxygenation of MI in these preparations was 
434 predominantly a monophasic reaction, carried out by FMO1.7 Catalytic 
435 activities of pulmonary FMO were investigated in rat pulmonary microsomes 
436 monitoring the change in absorbance at 412 nm for 7 min after the addition of 
437 a single dose (500 mM) of MI to the incubations. This experiment was repeated 
438 with 500 mM of MPTU added to the incubations and comparing the curves 
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439 obtained to those generated by incubations containing only MI or buffer. 
440 Obvious non competitive inhibition was noted, as indicated by the striking 
441 reduction in the absorbance change following the addition of the test article to 
442 the microsomal preparations (Figure 10B). 
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444 Acute pulmonary toxicity caused by molecules containing a thiourea moiety, 
445 including the thiourea-based compound ANTU, is characterized by acute 
446 pulmonary edema resulting from increased vascular permeability,30 similarly 
447 to what we observed with our test article, methylphenylthiourea (MPTU). Our 
448 results confirm that paracellular gap formation in pulmonary capillary 
449 endothelial cells represents the most likely morphological equivalent of the 
450 increased permeability. Structural damage to endothelial cells was mild in our 
451 studies and likely contributed only to a minor extent. The pulmonary 
452 architecture was well preserved and there was no loss of integrity of the 
453 alveolar epithelial cell lining, indicating that the epithelial compartment does 
454 not represent a (primary) target of thiourea toxicity. 
455 We then assessed the development of tolerance in the lung of rats 
456 administered sublethal doses of MPTU and investigated the pulmonary 
457 changes that contribute to the decreased susceptibility of tolerant rats to high, 
458 normally lethal doses of this thiourea-derived molecule. Barton et al. achieved 
459 complete protection from a lethal dose of ANTU (70 mg/kg) in rats 
460 administered a low, single dose (5 mg/kg) 24 hr before challenge with the high 
461 dose.12 In order to set up a tolerogenic regimen for our test article, a 
462 tolerogenic:lethal dose ratio similar to that reported by Barton et al. was used 
463 and the rats were initially given a dose (0.5 mg/kg) of MPTU which was 10 × 
464 lower than the LD50 (5 mg/kg). In none of the previous studies rats were 
465 challenged with the lethal dose before 24 hr after tolerance induction;11-13  
466 surprisingly, we found that protection against the high dose challenge was 
467 already effective as early as 3 hr after the administration of the tolerogenic 
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468 dose. This indicates that tachyphylaxis induced by thiourea-based molecules 
469 may represent an extremely effective protective mechanism that develops 
470 more rapidly than previously thought.12 As expected, tolerant animals only 
471 showed very mild clinical signs that were paralleled by the ultrastructural 
472 evidence of occasional endothelial bleb formation, irregular endothelial lining 
473 and rare paracellular gap formation. These findings were similar to but 
474 considerably less severe than those observed in the animals that had received 
475 only the lethal dose. This suggests that while the pathological processes 
476 induced by MPTU are not affected during the tolerogenic response, their 
477 degree is reduced, producing milder effects on the air blood barrier. Similar to 
478 other investigations,12,13 we also observed severe clinical signs and pulmonary 
479 edema  in previously tolerant rats challenged after 14 d with the lethal dose of 
480 MPTU, suggesting that the protection conferred by a tolerogenic dose is 
481 phasing out within 2 weeks.
482 Both histology and immunohistology concurred to demonstrate identify a trend 
483 towards a substantial increase in the number of macrophages and type II 
484 pneumocytes in the lungs of tolerant rats when compared to controls and high 
485 dose rats. The differing kinetic behavior of these cell populations is interesting: 
486 the early reaction (at 3, 6 and 24 hr pd) was represented by an influx of alveolar 
487 macrophages into the alveolar lumen, whilst type II pneumocytes began 
488 appeared to increase in number at 24 hr pd and reached maximum levels on 
489 day 7. On day 14, the number of both alveolar macrophages and type II 
490 pneumocytes had seemed to have almost returned to the levels observed in 
491 the controls. The rise in macrophages and type II pneumocytes appeared to 
492 be time- rather than dose-dependent, as the increases were of a similar degree 
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493 both in rats given the low dose only or the combined doses. The ultrastructural 
494 examination of type II epithelial cells allowed an important distinction: whilst 
495 the lungs of the tolerant rats at day 7 were predominantly populated by type II 
496 epithelial cells exhibiting numerous large lamellar bodies, the alveolar septa of 
497 rats euthanized at 6 and 24 hr pd exhibited numerous undifferentiated 
498 epithelial cells, with intermediate features between type I and type II 
499 pneumocytes. The transient appearance of an intermediate epithelial cell 
500 phenotype is consistent with differentiation of type II pneumocytes into type I 
501 pneumocytes following alveolar damage, as previously described.27-29, 31 This 
502 concept explains the low number of PCNA-positive cells observed at the 24 hr 
503 endpoint, suggesting that differentiation of type II pneumocytes into type I cells 
504 started shortly after MPTU-induced injury of the alveolar unit. The proliferation 
505 of type II cells observed at the later stage, evidenced by the increase in PCNA-
506 positive cells at 7 d pd, likely represents a second phase. 
507 A considerable amount of literature has been published looking into the 
508 defense mechanisms which are supposed to play a role in the adaptive 
509 response of the lungs following exposure to sublethal doses of thiourea-based 
510 molecules.2,12-13 Several reports suggested that alveolar epithelial hyperplasia 
511 protects rodents from oxidative injury induced by hyperoxia,32 bleomycin,33,34 
512 and hydrogen peroxide,35 as increased cellularity in the alveolius may 
513 strengthen the alveolar barrier, enhance the clearance of alveolar fluid36,37  
514 and/or influence the levels of inflammatory mediators and oxygen radical 
515 scavengers in the lung.14 Our work showed that protection from a lethal dose 
516 of MPTU is achieved after only 3 hr from the administration of a tolerogenic 
517 dose, when there is no morphologic evidence of an increased number of cells 
Page 26 of 53
For Review Purposes Only - Do Not Cite www.toxpath.org






























































518 in the lungs. This suggests that clearance of alveolar fluid by increased 
519 numbers of alveolar macrophages and type II pneumocytes in the lungs of 
520 tolerant rats may well contribute to the amelioration of the respiratory distress 
521 observed after the first few hours, but it is unlikely the primary mechanism 
522 associated with the development of tolerance.
523 With this in mind, we speculated that the adaptive response could have 
524 resulted from an enhancement of the antioxidant defense system. It is well 
525 known that the lungs are able to upregulate their protective antioxidant 
526 scavenging systems when exposed to mild oxidative injury, as occurs for 
527 instance in the lungs of chronic smokers.38 This is usually achieved by 
528 increasing the expression of antioxidant enzymes such as superoxide 
529 dismutase or, more frequently, glutathione peroxidase, which leads to larger 
530 amounts of GSH available to counteract the oxidative insult. This mechanism 
531 is unlikely to have an important role in the adaptive process that occurs in 
532 MPTU-tolerant lungs, as we observed GSH levels that were appeared to be at 
533 all time points similar to or lower than those found in the control rats.
534 Several drugs are able to modulate the levels of FMO expression in different 
535 tissues, either directly or through stimulation of an inflammatory response and 
536 production of inflammatory mediators, such as nitric oxide.39 Recently, 
537 upregulation of FMO3 has been described as a possible factor contributing to 
538 the development of resistance to hepatotoxicity caused by paracetamol in 
539 mice.40 We thought this could also be the case for MPTU and hypothesized 
540 that tolerance to thioureas might depend on the downregulation of FMO 
541 expression in the lungs and consequently decreased levels of the enzymes 
542 that are able to catalyze the oxygenation of these molecules to the reactive 
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543 intermediates responsible for the oxidative injury. We found significantly higher 
544 FMO1 and FMO2 mRNA levels in tolerant rats compared to controls, indicating 
545 that the decreased susceptibility to pulmonary oxidative injury in tolerant rats 
546 does not rely on the downregulation of the enzymes responsible for the 
547 metabolism of thiourea-based molecules.3 
548 It remained to be explored whether tolerance could be consistent with a 
549 mechanism of noncompetitive inhibition of FMOs, according to which the 
550 metabolic products of MPTU would have an inhibitory effect on the enzyme, 
551 even directly or through the formation of protein adducts or complexes with 
552 FMOs, leading to its inactivation. Indeed, addition of the test article to lung 
553 microsomal preparations prevented FMO-mediated oxygenation of MI, 
554 indicating inhibition of FMO activity. Although time-dependent inhibition has 
555 not been previously described for FMOs, it is known to alter the potency and 
556 influence the activity of cytochrome P450 (CYP).41 It is characterized by 
557 irreversible or quasi-irreversible inactivation of the enzyme, which causes lack 
558 of function of CYP until new protein is synthesized, typically after several 
559 days.41 Therefore, the transient (less than 14 days) duration of MPTU-induced 
560 tolerance, coupled with increased synthesis of FMO1 and FMO2 mRNA, is 
561 appears to be consistent with a time-dependent inhibition of FMOs which is 
562 then progressively lost with synthesis of new protein.41 The outcome of these 
563 experiments provides preliminary in vitro evidence of irreversible FMO 
564 inhibition by MPTU and might lead to a possible mechanistic explanation for 
565 the acquired tolerance. It needs confirmation by ex vivo approaches, i.e. the 
566 testing of FMO activity in microsomes obtained directly from rats exposed to 
567 MPTU and euthanized at different time points. Also, we used a single 
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568 tolerogenic dose in both our in vitro and in vivo studies, while it would be 
569 interesting to investigate the effectiveness of MPTU in inducing tolerance, and 
570 the associated morphological changes resulting from a range of tolerogenic 
571 doses in order to confirm the mode of action of MPTU. The role of FMO 
572 inhibition in the development of tolerance to MPTU (and possibly to other 
573 oxidative scavengers) could also be addressed by using different synthetic 
574 FMO inhibitors in both in vitro and in vivo experiments. Furthermore, the small 
575 group size (n=3) and the inclusion of only one control group at 24 hr represents 
576 a limitations of the tolerancebility study. Group numbers were determined 
577 based on the outcomes of pilot toxicity studies, which showed limited variability 
578 of the evaluated parameters within a dose group; they were deemed sufficient 
579 for this exploratory research work and are in line with the 3Rs principles. 
580 However, caution must be applied when generalizing the findings beyond the 
581 context of this study. 
582 The model of ALI caused by phenylthiourea shares numerous features with 
583 ARDS, a severe human pulmonary condition characterized by diffuse acute 
584 oxidative damage of the alveolar unit, which is not completely understood to 
585 date and difficult to treat.42 All available animal models of ALI aim to reproduce 
586 the mechanisms and consequences observed in humans by inducing 
587 significant damage to the alveolar epithelium, which is followed by a reparative 
588 process.42 The main limitation of experimental models of ALI is that none fully 
589 recapitulate the features of lung injury in humans. Thioureas may represent an 
590 interesting and unique model of ALI, where the primary injury affects the 
591 endothelial cells rather than the epithelial compartment, similar to oleic acid 
592 and endotoxin, which are commonly used as ALI models that target mainly the 
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593 capillary endothelium.42 In addition, further understanding of the mechanisms 
594 involved in the development of tolerance to thiourea-induced ALI might be 
595 helpful to develop therapeutic strategies aimed at reducing the severity of lung 
596 injury. For example, it would be interesting to test whether cell proliferation 
597 induced by small doses of MPTU can protect the lungs from ALI caused by 
598 different noxious agents such as toxic gases, hyperoxia, endotoxins and viral 
599 infection, and more recently, e-cigarette vaping43 and whether this could be of 
600 clinical relevance. Future studies should assess the significance of the 
601 pulmonary responses to this type of injury and determine whether they still 
602 represent a reparative process or are instead an adaptive reaction, aimed to 
603 confer protection from further injury. With this in mind, the investigation of 
604 these protective mechanisms may bring new insight into the therapeutic 
605 approach to ALI and ARDS in humans. 
606
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608 Figure 1. Potential mechanisms underlying tolerance to MPTU addressed in the 
609 present study include increased clearance of alveolar fluid, increased antioxidant 
610 defenses, and reduced FMO activity. The molecule depicted in the drawing is 
611 phenylthiourea. Phenylthiourea (1) is transformed into a phenylthiourea reactive 
612 intermediate, i.e. a sulfenic acid (2) with consumption of GSH. The S-oxidation of the 
613 molecule is carried out by FMOs. Redrawn from Smith and Crespi (2002).44 
614 Figure 2. Schematic timeline representation of the 14 day tolerance experiment. n: 
615 number of rats euthanized at each time point. Group sizes for each time point are n = 
616 3. MPTU: methylphenylthiourea.
617 Figure 3. Macroscopic features of MPTU-induced acute lung toxicity. Severe 
618 hydrothorax (*) in a rat administered a high dose (5 mg/kg) of MPTU and euthanized 
619 6 hr post dosing.
620 Figure 4. Microscopic features of MPTU-induced acute lung toxicity. (A-D) Severe 
621 alveolar and interstitial edema, represented by proteinaceous fluid filling the alveolar 
622 lumen (B, *) and the perivascular space (D, double-headed arrow) of the same rat as 
623 in figure 3 (5 mg/kg) of MPTU). Figures A and C show normal alveoli and interstitial 
624 space in a control rat lung for comparison. Hematoxylin and eosin stain. Bars: 20 µm. 
625 (E-F) Apoptotic alveolar lining cells are observed in the lungs of a treated rat (F, arrow) 
626 compared to a control lung (E) where no apoptotic cells are detected. Cleaved 
627 caspase 3 immunohistochemistry. Bars: 20 µm.
628 Figure 5. Ultrastructural features of MPTU-induced acute lung toxicity. (A) Normal 
629 alveolar unit in a control rat. Type I pneumocytes are separated from the underlying 
630 capillary endothelial cells by a fused continuous basal lamina (arrowhead). (B-D) 
631 Treated rat administered with a high dose (5 mg/kg) of MPTU and euthanized 6 hr 
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632 post dosing. (B) Subendothelial blebs (arrow) in the alveolar unit. (C) Inter-endothelial 
633 cell gap (open arrowhead) in the vicinity of the cellular junction, alongside a 
634 subendothelial bleb (arrow). Apoptotic endothelial cells (solid arrowhead) are 
635 observed infrequently. (D) Proteinaceous fluid in the air-blood barrier (arrows) and the 
636 alveolar lumen (*). Bars: 2 µm.
637 Table 1. Summary of the key histological findings in MPTU-induced pulmonary toxicity 
638 and tolerance. Results are expressed as number of animals showing the histological 
639 finding/number of animals per group. The average severity of each finding [in 
640 brackets] was calculated by summing the severity grades and dividing the total by the 
641 number of animals affected by that finding.
642 Figure 6. Microscopic features of MPTU-induced tolerance in the lungs. (A-D) 
643 Compared to the control lungs (A), type II pneumocyte hyperplasia is evident at 24 hr 
644 post dosing (pd) (B), increases in severity at day 7 pd and is no longer present on day 
645 14 pd (D). In each figure, the right panel shows the SP-C immunohistology for type II 
646 pneumocytes (arrows). (E-F) Compared to the control lungs (E), in which no PCNA-
647 positive alveolar cells are noted, staining for PCNA reveals an increase in proliferating 
648 alveolar lining epithelial cells (arrows) consistent with type II pneumocytes at day 7 pd 
649 (F). Bars: 10 µm.
650 Figure 7. Immunohistological features (cell count) of MPTU-induced tolerance in the 
651 lungs. (A) Percentages of total cells expressing SP-C (type II pneumocytes). An 
652 increase in type II pneumocytes is observed on day 7 pd. (B) Number of cells in the 
653 alveolius expressing PCNA. An increase is evident on day 7 pd. (C) Percentages of 
654 cells within the alveolar lumen expressing lysozyme (alveolar macrophages). An 
655 increase is observed at the 6 hr and 24 hr pd. Data are presented as mean percentage 
656 of positive cells/total cells/field/animal (SP-C, lysozyme) or number of positive 
657 cells/field/animal (PCNA). The height of the bars and the number within each bar 
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658 represent the median. HD: high dose of MPTU (5 mg/kg). LD: low dose of MPTU 
659 (0.5 mg/kg).
660
661 Figure 8. Ultrastructural features of MPTU-induced tolerance in the lungs. (A) 
662 Subendothelial bleb (arrowhead) in the alveolar unit of a tolerant rat (0.5 mg/kg + 
663 5 mg/kg of MPTU, 24 hr pd). (B) An immature pneumocyte (arrowhead) in the 
664 alveolius of a tolerant rat (0.5 mg/kg of MPTU, 24 hr pd). (C) Numerous immature 
665 pneumocytes (arrowheads) in the alveolar unit of a tolerant rat (0.5 mg/kg of MPTU) 
666 euthanized 24 hr pd, together with type II pneumocytes (arrows). (D) Numerous type 
667 II pneumocytes (arrows) in the lungs of a tolerant rat (0.5 mg/kg of MPTU) at 7 d pd. 
668 Bars: 2 µm.
669 Figure 9. GSH levels and FMO expression in the lungs of rats administered the high 
670 dose (HD, 5 mg/kg) of MPTU, the low dose alone (LD, 0.5 mg/kg) or the LD, followed 
671 3 hr later by the HD (LD + HD). (A) An increase in GSH levels is seen at the 6 hr pd 
672 time points, also in the rat cohorts challenged with the HD on day 14 and euthanized 
673 6 hr later (bold outlines). (B) qPCR analysis showing significantly higher levels of 
674 relative expression (fold change) of FMO1 and FMO2 in the lungs of rats following 
675 exposure to high and low doses of MPTU. The height of the bars and the number 
676 within each bar represent the median. * p < 0.05 ** p < 0.01 (Kruskal Wallis non 
677 parametric ANOVA)
678 Figure 10. Catalytic activities of FMO in rat pulmonary microsomes and enzyme 
679 inhibition using MPTU. (A) Enzyme kinetics of the sulphoxygenation of methimazole 
680 (MI) deduced from the Michaelis Menten equation. Reaction velocity is plotted in an 
681 Eadie-Hofstee diagram against the ratio between velocity and substrate concentration 
682 and is represented by a monophasic reaction. Data points for each replicate are 
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683 represented. Dashed lines indicate the 95% confidence intervals for the regression 
684 line. Vmax: maximum velocity of the reaction. Km: Michaelis-Menten constant. (b) MI 
685 (500 mM) oxygenation rates over time (7 min) and inhibitory activity of MPTU on the 
686 sulphoxygenation of MI. Difference in absorbance (ΔOD) is plotted against time. Data 
687 are presented as median ± standard deviation for n=9 (three different measurements 
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0 24 hr 0/3 0/3 0/3 0/3
5 6 hr 3/3 [2.6] 3/3 [2] 0/3 2/3 [1.5]
3 hr 0/3 3/3 [1.6] 0/3 0/3
6 hr 0/3 3/3 [2] 0/3 0/3
24 hr 0/3 3/3 [2] 2/3 [1] 0/3
7 d 0/3 1/3 [1] 3/3 [1.3] 0/3
0.5
14 d 0/3 1/3 [1] 0/3 0/3
24 hr 1/3 [2] 3/3 [3] 2/3 [1.3] 1/3 [2]
7 d 0/3 2/3 [1.5] 3/3 [2] 0/3
0.5 + 5
(3 hr later)
14 d 0/3 2/3 [1] 1/3 [1] 0/3
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Potential mechanisms underlying tolerance to MPTU addressed in the present study include increased 
clearance of alveolar fluid, increased antioxidant defences, and reduced FMO activity. The molecule depicted 
in the drawing is phenylthiourea. Phenylthiourea (1) is transformed into a phenylthiourea reactive 
intermediate, i.e. a sulfenic acid (2) with consumption of GSH. The S-oxidation of the molecule is carried out 
by FMOs. Redrawn from Smith and Crespi (2002).44 
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Schematic timeline representation of the 14 day tolerance experiment. n: number of rats euthanized at each 
time point. Group sizes for each time point are n = 3. MPTU: methylphenylthiourea. 
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Macroscopic features of MPTU-induced acute lung toxicity. Severe hydrothorax (*) in a rat administered a 
high dose (5 mg/kg) of MPTU and euthanized 6 hr post dosing. 
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Microscopic features of MPTU-induced acute lung toxicity. (A-D) Severe alveolar and interstitial edema, 
represented by proteinaceous fluid filling the alveolar lumen (B, *) and the perivascular space (D, double-
headed arrow) of the same rat as in figure 3 (5 mg/kg) of MPTU). Figures A and C show normal alveoli and 
interstitial space in a control rat lung for comparison. Hematoxylin and eosin stain. Bars: 20 µm. (E-F) 
Apoptotic alveolar lining cells are observed in the lungs of a treated rat (F, arrow) compared to a control 
lung (E) where no apoptotic cells are detected. Cleaved caspase 3 immunohistochemistry. Bars: 20 µm. 
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Ultrastructural features of MPTU-induced acute lung toxicity. (A) Normal alveolar unit in a control rat. Type I 
pneumocytes are separated from the underlying capillary endothelial cells by a fused continuous basal 
lamina (arrowhead). (B-D) Treated rat administered with a high dose (5 mg/kg) of MPTU and euthanized 6 
hr post dosing. (B) Subendothelial blebs (arrow) in the alveolar unit. (C) Inter-endothelial cell gap (open 
arrowhead) in the vicinity of the cellular junction, alongside a subendothelial bleb (arrow). Apoptotic 
endothelial cells (solid arrowhead) are observed infrequently. (D) Proteinaceous fluid in the air-blood barrier 
(arrows) and the alveolar lumen (*). Bars: 2 µm. 
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Microscopic features of MPTU-induced tolerance in the lungs. (A-D) Compared to the control lungs (A), type 
II pneumocyte hyperplasia is evident at 24 hr post dosing (pd) (B), increases in severity at day 7 pd and is 
no longer present on day 14 pd (D). In each figure, the right panel shows the SP-C immunohistology for 
type II pneumocytes (arrows). (E-F) Compared to the control lungs (E), in which no PCNA-positive alveolar 
cells are noted, staining for PCNA reveals an increase in proliferating alveolar lining epithelial cells (arrows) 
consistent with type II pneumocytes at day 7 pd (F). Bars: 10 µm. 
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Immunohistological features (cell count) of MPTU-induced tolerance in the lungs. (A) Percentages of total 
cells expressing SP-C (type II pneumocytes). An increase in type II pneumocytes is observed on day 7 pd. 
(B) Number of cells in the alveolius expressing PCNA. An increase is evident on day 7 pd. (C) Percentages of 
cells within the alveolar lumen expressing lysozyme (alveolar macrophages). An increase is observed at the 
6 hr and 24 hr pd. Data are presented as mean percentage of positive cells/total cells/field/animal (SP-C, 
lysozyme) or number of positive cells/field/animal (PCNA).HD: high dose of MPTU (5 mg/kg). LD: low dose 
of MPTU (0.5 mg/kg). 
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Ultrastructural features of MPTU-induced tolerance in the lungs. (A) Subendothelial bleb (arrowhead) in the 
alveolar unit of a tolerant rat (0.5 mg/kg + 5 mg/kg of MPTU, 24 hr pd). (B) An immature pneumocyte 
(arrowhead) in the alveolus of a tolerant rat (0.5 mg/kg of MPTU, 24 hr pd). (C) Numerous immature 
pneumocytes (arrowheads) in the alveolar unit of a tolerant rat (0.5 mg/kg of MPTU) euthanized 24 hr pd, 
together with type II pneumocytes (arrows). (D) Numerous type II pneumocytes (arrows) in the lungs of a 
tolerant rat (0.5 mg/kg of MPTU) at 7 d pd. Bars: 2 µm. 
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GSH levels and FMO expression in the lungs of rats administered the high dose (HD, 5 mg/kg) of MPTU, the 
low dose alone (LD, 0.5 mg/kg) or the LD, followed 3 hr later by the HD (LD + HD). (A) An increase in GSH 
levels is seen at the 6 hr pd time points, also in the rat cohorts challenged with the HD on day 14 and 
euthanized 6 hr later. (B) qPCR analysis showing higher levels of relative expression (fold change) of FMO1 
and FMO2 in the lungs of rats following exposure to high and low doses of MPTU. 
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Catalytic activities of FMO in rat pulmonary microsomes and enzyme inhibition using MPTU. (A) Enzyme 
kinetics of the sulphoxygenation of methimazole (MI) deduced from the Michaelis Menten equation. Reaction 
velocity is plotted in an Eadie-Hofstee diagram against the ratio between velocity and substrate 
concentration and is represented by a monophasic reaction. Data points for each replicate are represented. 
Dashed lines indicate the 95% confidence intervals for the regression line. Vmax: maximum velocity of the 
reaction. Km: Michaelis-Menten constant. (b) MI (500 mM) oxygenation rates over time (7 min) and 
inhibitory activity of MPTU on the sulphoxygenation of MI. Difference in absorbance (ΔOD) is plotted against 
time. 
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Morphological and mechanistic aspects of thiourea-induced acute lung 
injury and tolerance in the rat
G. Pellegrini1, D. Williams2, S. Hughes3, R. Sharples3, B.K.Park4, and A. 
Kipar1,5.
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Swine anti Rabbit 
IgG
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TBST (Dako Z0196)
PAP Rabbit
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PAP Rabbit
1:20 in 20% ss 
in TBST
ss = swine serum. TBST = 1× TBS Buffer + 0.05% Tween 20
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RT-qPCR for FMO1 and FMO2 mRNA quantification











































Thermal cycling conditions of target and reference gene qPCR amplification. 
Step t C° Time 
Number of 
cycles
Initial denaturation 94 10 min 1
Denaturation 94 30 sec
Annealing
60 (FMO1 and GAPDH2)
63.5 (FMO2 and GAPDH1)
30 sec
Extension 72 30 sec
Primer dimer melt off 75 1 sec
Plate reading - -
35
Final extension 72 5 min 1
Melting temperature 65-95 (increment 0.2/sec) 1
Soak 4 indefinite 1
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